Taiho Oncology

Executive Summary

Taiho Oncology is a private biopharmaceutical company headquartered in Princeton, New Jersey, with a mission to bring innovative small-molecule therapies to cornerstone chemotherapies for a wide range of tumor types, including colorectal cancer and various solid tumors. Founded in 2006, the company leverages its deep expertise in oncology to develop novel treatments that improve outcomes for patients. As a private entity, Taiho Oncology operates with a focused strategy, prioritizing research and development in areas of high unmet medical need. The company's commitment to advancing cancer care is evident in its portfolio, which targets both established and emerging pathways in tumor biology. While specific pipeline details are not publicly available, Taiho Oncology's emphasis on small molecules positions it within a competitive landscape where targeted therapies and precision medicine are driving innovation. The company's ability to navigate regulatory pathways and bring new options to market will be critical to its long-term success.